Market Overview

UPDATE: BMO Capital Markets Initiates Abbott Laboratories at Outperform on Growth, Margin Expansion

Related ABT
Inversion Crackdown Leaves Several Deals In Limbo
Top 4 NYSE Stocks In The Medical Appliances & Equipment Industry With The Highest Revenue
Buyback Mania Inflates 2Q Earnings Growth (Fox Business)

BMO Capital Markets initiated coverage on Abbott Laboratories (NYSE: ABT) with an Outperform rating and a $36 price target.

BMO Capital Markets noted, "The new Abbott is expected to deliver 2012E sales of $21.5B (flat; up 4% ex-FX) from four distinct businesses: Nutritionals (30% of sales); Medical Products (26%); Established Pharmaceuticals (24%); and Diagnostics (20%). With leading market share positions and an extensive geographic footprint, particularly in the emerging markets (about 40% of revenue), we expect the company to benefit from a focused management team and dedicated resources, to drive mid- to high-single-digit revenue growth, expand operating margins, and deliver double-digit EPS."

Abbott Laboratories closed at $31.40 on Monday.

Latest Ratings for ABT

DateFirmActionFromTo
Jul 2014BarclaysMaintainsEqual-weight
Jul 2014Raymond JamesMaintainsOutperform
Jul 2014JefferiesMaintainsBuy

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters